五星体育直播 to Commercially Supply Proprietary Enzyme to Tate & Lyle
REDWOOD CITY, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- 五星体育直播 (NASDAQ:CDXS), a leading protein engineering company, today announced that it has entered into an exclusive agreement with Tate & Lyle, a global provider of ingredients and solutions, to supply a proprietary enzyme for use in the company鈥檚 food ingredient production.
鈥淲e are delighted to move our partnership with Tate & Lyle to the commercial level,鈥� said 五星体育直播 President and CEO John Nicols. 鈥淭his agreement further validates the ability of our CodeEvolver庐 protein engineering platform technology to improve and support manufacturing processes, in this case in the food industry. Expanding application of our technology to new markets has been a strategic priority for 五星体育直播 and establishing this agreement is a notable achievement.鈥�
About CodeEvolver庐 Protein Engineering Platform Technology
CodeEvolver庐 is 五星体育直播鈥� proprietary protein engineering platform, which enables the rapid development of custom-designed enzymes that are highly optimized for a specific function. The CodeEvolver庐 platform is comprised of proprietary methods for the optimization of proteins through the design and generation of diverse genetic libraries, automated screening techniques, algorithms for the interpretation of screening data and predictive modelling. The CodeEvolver庐 platform technology is covered by approximately 225 issued patents and pending patent applications worldwide.聽
About 五星体育直播
五星体育直播 is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals. 五星体育直播鈥� proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see .
About Tate & Lyle
Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations in over 30 locations worldwide.
Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups.
The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.
Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA庐聽Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.
Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.
Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2016, Tate & Lyle sales totalled 拢2.4 billion. For more information, please visit
SPLENDA庐聽is a trademark of Heartland Consumer Products LLC.
Forward-Looking Statements
This press release contains forward-looking statements relating to 五星体育直播鈥� supply agreement with Tate & Lyle, including 五星体育直播鈥� belief that this agreement further validates the ability of our CodeEvolver庐 protein engineering platform technology to improve and support manufacturing processes, in this case in the food industry. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond 五星体育直播鈥� control and that could materially affect actual results. Factors that could materially affect actual results include 五星体育直播鈥� dependence on its licensees and collaborators; 五星体育直播鈥� dependence on a limited number of products and customers in its pharmaceutical business; potential adverse effects to 五星体育直播鈥� business if its customers鈥� pharmaceutical products are not received well in the markets; 五星体育直播鈥� ability to deploy its technology platform in new market spaces; 五星体育直播鈥� dependence on key personnel; 五星体育直播鈥� ability to compete may decline if it loses some of its intellectual property rights; third party claims that 五星体育直播 infringes third party intellectual property rights; and 五星体育直播 could face increased competition if third parties misappropriate 五星体育直播 biocatalysts. Additional factors that could materially affect actual results can be found in 五星体育直播鈥� Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 8, 2016 and in 五星体育直播鈥� Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2016, including, in each case, under the caption 鈥淩isk Factors.鈥� 五星体育直播 expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
CONTACT: Investors LHA Jody Cain, 310 691 7100 jcain@lhai.com Media That鈥檚 Nice Guy Tiene, 212 366 4455 guy@thatsnice.comSource: 五星体育直播
Released December 6, 2016